Casandra
Casandra Test Code NG98880Version 1 (DRAFT)
Performing Lab
Lab NeoGenomicsLab Test ID N/A
FOLR1 FDA (ELAHERE™) for Ovarian Carcinoma
Also known as: FOLR1 IHC CDx, Folate Receptor alpha (FR?), FOLR1 (FOLR1-2.1) RxDx Assay, FR-ASSIST™ VENTANA FOLR1 (FOLR1-2.1)
Clinical Use
Order TestUse
The FR? protein is expressed in 90% of ovarian cancers and has limited expression in normal tissue, making it an attractive therapeutic target. In using the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay for the evaluation of ovarian cancer patients, approximately 35% of patients are considered to have high expression of FR?—as defined by the scoring criteria mentioned above— and thus eligible for treatment with ELAHERE™.
Special Instructions
Not provided.
Limitations
Not provided.
Test Details
FDA ApprovedNew York Approved
Methodology
IHC
Biomarkers
Targets not provided.
Result Turnaround Time
2 days
Related Documents
For more information, please review the documents below
Specimen Requirements
Specimen
FFPE Tissue
Volume
Not provided
Minimum Volume
Not provided